Literature DB >> 19629030

Creation of murine experimental abdominal aortic aneurysms with elastase.

Junya Azuma1, Tomoko Asagami, Ronald Dalman, Philip S Tsao.   

Abstract

Transient intraluminal infusion of porcine pancreatic elastase into the infrarenal segment of the abdominal aorta is the most widely used animal model of abdominal aortic aneurysm (AAA) ever since it was first described in rats by Anidjar and colleagues.(1) The rationale for its development was based on the disrupted nature of elastin observed in AAAs. This rat model has been modified to produce AAAs in the infrarenal aortic region of mice.(2) The model has the ability to add broad insight into the pathobiology of AAA due to the emergence of numerous transgenic and gene knockout mice. Moreover, it is a viable platform to test potential therapeutic agents for AAA. In this video, we demonstrate the elastase infusion AAA procedure used in our laboratory. Mice are anesthetized using 2.5% isoflurane, and a laparotomy is performed under sterile conditions. The abdominal aortais isolated with the assistance of an operating stereomicroscope (Leica). After placing temporary ligatures around the proximal and distal aorta, an aortotomy is created at the bifurcation with the tip of a 30-gauge needle. A heat-tapered segment of PE-10 polyethylene tubing is introduced through the aortotomy and secured. The aortic lumen is subsequently perfused for 5-15 minutes at 100 mm Hg with saline containing type I porcine pancreatic elastase (4.5 U/mL; Sigma Chemical Co.). After removing the perfusion catheter, the aortotomy is repaired without constriction of the lumen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629030      PMCID: PMC3148686          DOI: 10.3791/1280

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  3 in total

1.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Elastase is not sufficient to induce experimental abdominal aortic aneurysms.

Authors:  C G Carsten; W C Calton; J M Johanning; P J Armstrong; D P Franklin; D J Carey; J R Elmore
Journal:  J Vasc Surg       Date:  2001-06       Impact factor: 4.268

3.  Elastase-induced experimental aneurysms in rats.

Authors:  S Anidjar; J L Salzmann; D Gentric; P Lagneau; J P Camilleri; J B Michel
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

  3 in total
  26 in total

Review 1.  Three-dimensional microstructural changes in murine abdominal aortic aneurysms quantified using immunofluorescent array tomography.

Authors:  Sanaz Saatchi; Junya Azuma; Nishey Wanchoo; Stephen J Smith; Paul G Yock; Charles A Taylor; Philip S Tsao
Journal:  J Histochem Cytochem       Date:  2011-12-01       Impact factor: 2.479

2.  Influences of aortic motion and curvature on vessel expansion in murine experimental aneurysms.

Authors:  Craig J Goergen; Junya Azuma; Kyla N Barr; Lars Magdefessel; Dara Y Kallop; Alvin Gogineni; Amarjeet Grewall; Robby M Weimer; Andrew J Connolly; Ronald L Dalman; Charles A Taylor; Philip S Tsao; Joan M Greve
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 3.  Monocytes and macrophages in abdominal aortic aneurysm.

Authors:  Juliette Raffort; Fabien Lareyre; Marc Clément; Réda Hassen-Khodja; Giulia Chinetti; Ziad Mallat
Journal:  Nat Rev Cardiol       Date:  2017-04-13       Impact factor: 32.419

4.  Segmental aortic stiffening contributes to experimental abdominal aortic aneurysm development.

Authors:  Uwe Raaz; Alexander M Zöllner; Isabel N Schellinger; Ryuji Toh; Futoshi Nakagami; Moritz Brandt; Fabian C Emrich; Yosuke Kayama; Suzanne Eken; Matti Adam; Lars Maegdefessel; Thomas Hertel; Alicia Deng; Ann Jagger; Michael Buerke; Ronald L Dalman; Joshua M Spin; Ellen Kuhl; Philip S Tsao
Journal:  Circulation       Date:  2015-04-22       Impact factor: 29.690

5.  Hyperglycemia limits experimental aortic aneurysm progression.

Authors:  Noriyuki Miyama; Monica M Dua; Janice J Yeung; Geoffrey M Schultz; Tomoko Asagami; Eiketsu Sho; Mien Sho; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2010-08-03       Impact factor: 4.268

6.  Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development.

Authors:  Lars Maegdefessel; Junya Azuma; Ryuji Toh; Denis R Merk; Alicia Deng; Jocelyn T Chin; Uwe Raaz; Anke M Schoelmerich; Azad Raiesdana; Nicholas J Leeper; Michael V McConnell; Ronald L Dalman; Joshua M Spin; Philip S Tsao
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

7.  Suppression of aortic expansion and contractile recovery in a rat abdominal aortic aneurysm model by biodegradable gelatin hydrogel sheet incorporating basic fibroblast growth factor.

Authors:  Norikazu Kawai; Hisashi Iwata; Katsuya Shimabukuro; Narihiro Ishida; Hiroki Ogura; Etsuji Umeda; Kiyoshi Doi
Journal:  Heart Vessels       Date:  2017-12-28       Impact factor: 2.037

8.  A new murine model of endovascular aortic aneurysm repair.

Authors:  Martin Rouer; Olivier Meilhac; Sandrine Delbosc; Liliane Louedec; Graciela Pavon-Djavid; Jane Cross; Josette Legagneux; Maxime Bouilliant-Linet; Jean-Baptiste Michel; Jean-Marc Alsac
Journal:  J Vis Exp       Date:  2013-07-07       Impact factor: 1.355

9.  MicroRNA-26a is a novel regulator of vascular smooth muscle cell function.

Authors:  Nicholas J Leeper; Azad Raiesdana; Yoko Kojima; Hyung J Chun; Junya Azuma; Lars Maegdefessel; Ramendra K Kundu; Thomas Quertermous; Philip S Tsao; Joshua M Spin
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

10.  Targeted Gold Nanoparticles as an Indicator of Mechanical Damage in an Elastase Model of Aortic Aneurysm.

Authors:  Brooks A Lane; Xiaoying Wang; Susan M Lessner; Naren R Vyavahare; John F Eberth
Journal:  Ann Biomed Eng       Date:  2020-04-02       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.